Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Titan with enough to fund planned operations through the third quarter of 2019, Probuphine well-positioned for global success
April 1, 2019 Off

Titan with enough to fund planned operations through the third quarter of 2019, Probuphine well-positioned for global success

By Dino Mustafić

Titan’s President and CEO, Sunil Bhonsle said that the second half of 2018 as the company’s rapid advancement toward becoming a commercial-stage company following its assumption of responsibility for Probuphine sales in the U.S. starting mid-June.

AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
April 1, 2019 Off

AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update

By BusinessWire

Ends 2018 with triad of innovative cell therapy technologies: UniverCyte™ for immune tolerance, PureStem® for cell derivation and manufacturing, and…

April 1, 2019 Off

Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals

By BusinessWire

KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Merck [NYSE:MRK], known as MSD outside the United States and Canada, today announced…

April 1, 2019 Off

Tricida Announces Proposed Public Offering of Common Stock

By BusinessWire

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares…

Novartis buys IFM Tre for $1.575 Billion from IFM Therapeutics
April 1, 2019 Off

Novartis buys IFM Tre for $1.575 Billion from IFM Therapeutics

By Dino Mustafić

Novartis has purchased a subsidiary of IFM Therapeutics LLC focused on developing ani-inflammatory medicines targeting the NLRP3 inflammasome, which will add one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system.

April 1, 2019 Off

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics,…

April 1, 2019 Off

AmerisourceBergen Announces Date and Time for Second Quarter Fiscal 2019 Earnings Release

By BusinessWire

VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter…

April 1, 2019 Off

Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today…

April 1, 2019 Off

Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the…

April 1, 2019 Off

AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML

By BusinessWire

– Data presented during poster session at the AACR 2019 Annual Meeting – CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ:AVEO) and Biodesix,…

Posts pagination

Previous 1 … 3,313 3,314 3,315 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine